Murphy G P, Mirand E A, Sinks L F, Allen J E, Staubitz W J
J Urol. 1975 Feb;113(2):230-3. doi: 10.1016/s0022-5347(17)59451-3.
Measurement of erythropoietin levels was achieved in urine, plasma and tumor extract specimens in 27 Wilms tumor patients. Good correlation of the stage of the disease, the clinical judgment of inactive or responding tumor foci and erythropoietin levels was noted. Erythropoietin levels are believed to reflect ectopic hormone production by the primary or secondary tumor. Since the erythropoietin hormone assayed in these and other Wilms tumor patients was not associated with polycythemia, it is believed that Wilms tumor-associated erythropoietin differs in some manner from the hormone produced normally in man and possible in other states associated with secondary polycythemia. Etythropoietin assay with further purification and technical development can be of additional widespread assistance in the clinical classification and subsequent management of the tumor state. Our study confirms this biological potential.
对27例肾母细胞瘤患者的尿液、血浆和肿瘤提取物标本进行了促红细胞生成素水平的检测。结果发现疾病分期、无活性或有反应的肿瘤灶的临床判断与促红细胞生成素水平之间存在良好的相关性。促红细胞生成素水平被认为反映了原发性或继发性肿瘤的异位激素产生。由于在这些以及其他肾母细胞瘤患者中检测到的促红细胞生成素激素与红细胞增多症无关，因此认为肾母细胞瘤相关的促红细胞生成素在某种程度上不同于人体正常产生的激素，也可能不同于与继发性红细胞增多症相关的其他状态下产生的激素。随着进一步的纯化和技术发展，促红细胞生成素检测在肿瘤状态的临床分类和后续管理中可能会提供更多广泛的帮助。我们的研究证实了这种生物学潜力。
